Winship Helps Win FDA Approval for First Aggressive Leukemia Therapy
January 17, 2025
January 17, 2025
ATLANTA, Georgia, Jan. 17 -- Emory University Winship Cancer Institute issued the following news release:
The U.S. Food and Drug Administration (FDA) on November 15, 2024, approved revumenib--the first of a new class of drugs called menin inhibitors for aggressive, treatment-resistant leukemia. The FDA granted priority review for the revumenib application, designating the drug both a breakthrough and an orphan drug.
The FDA's approval is based on data from 104 adul . . .
The U.S. Food and Drug Administration (FDA) on November 15, 2024, approved revumenib--the first of a new class of drugs called menin inhibitors for aggressive, treatment-resistant leukemia. The FDA granted priority review for the revumenib application, designating the drug both a breakthrough and an orphan drug.
The FDA's approval is based on data from 104 adul . . .